Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoadjuvant Operable Breast Cancer × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 136 Endometrial Neoplasms 13 Ovarian Neoplasms 10 Recurrence 4 Neoplasms 4 Neoplasm Metastasis 4 Fallopian Tube Neoplasms 4 Carcinoma, Intraductal, Noninfiltrating 4 Breast Cancer Metastatic 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Lobular 2 Breast Diseases 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Polycystic Ovary Syndrome 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Pain 1 Osteoporosis 1 Neoplastic Cells, Circulating 1 Neoadjuvant Operable Breast Cancer 1 Multiple Endocrine Neoplasia Type 1 1 Medullary cystic kidney disease 1 1 Lymphangioleiomyomatosis 1 Low-Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡